Program
TQC3927
A development code. Also written as “TQC3927 powder for inhalation” and “TQC3927 inhalation aerosol”.
In Sino Biopharmaceutical's pipeline, MABA双靶
. Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 30 open or running | phase 2since Jun 3, 2026 | Apr 29, 2024 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQC3927
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 29, 2024First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT06408285 · 60 enrolled · China
- Nov 22, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06711991 · 48 enrolled · China
- Jun 3, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructivePhase 2 reachedNCT07633314 · 90 enrolled · China
TargetBeta
“MABA双靶”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TQC3302 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07633314Pulmonary Disease, Chronic Obstructive · China | 2 | Suspended | Dec 2026 | 90 |
| NCT06711991Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | Aug 11, 2025 | 48 |
| NCT06408285Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | Aug 19, 2024 | 60 |
How it is read
Names in the registry
- “TQC3927 powder for inhalation”, 2 entries
- “TQC3927 inhalation aerosol”, 1 entry
Codes read as this program: TQC3927.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.